RxDoctor Payments Data

Ruben Rhoades, MD

Internal Medicine · Philadelphia, PANPI 1093072944

Payments from drug & device makers

$67,042in general payments, 2019–2025

Across 18 payments — averaging $3724.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$62K
  • Novartis$3K
  • Sanofi$2K
  • Daiichi Sankyo Inc.$21
  • Octapharma USA, Inc.$21
  • Global Blood Therapeutics, Inc.$16

What the payments were for

  • Consulting fees$5,00096%
  • Food & beverage$1934%

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,042 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,630
Medicare patients
210
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GivlaariGivosiran Sodium12$511,490
JakafiRuxolitinib Phosphate22$462,058
PromactaEltrombopag Olamine19$221,081
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres17$114,360
EliquisApixaban78$80,321
RetacritEpoetin Alfa-Epbx17$23,315
XareltoRivaroxaban11$14,776
Enoxaparin Sodium12$6,400
Hydroxyurea83$2,620
Tranexamic Acid37$1,229
Cyclosporine ModifiedCyclosporine, Modified11$667
Morphine Sulfate ErMorphine Sulfate16$545
Warfarin Sodium40$379
Prednisone14$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta, Sandostatin Lar Depot$2,700$335,44136 claims
PfizerEliquis, Retacrit$61,849$103,63795 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →